+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Removal of basiliximab by plasmapheresis

American Journal of Kidney Diseases 37(1): E11-E11
Removal of basiliximab by plasmapheresis
Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 (IL-2) receptors. Given its expected volume of distribution (plasma volume), therapeutic plasmapheresis may be expected to lower serum Basiliximab levels. A 20-mg dose of Basiliximab was given before plasmapheresis. Blood and pheresis fluid samples were obtained to monitor Basiliximab levels. A total of three blood samples were drawn: the first was obtained 4 hours before, the second sample immediately before commencement, and the third 2 hours after cessation of plasmapheresis. A fourth sample was obtained from the removed plasma. There was an appreciable reduction in Basiliximab concentration levels after plasmapheresis. From the change in serum concentration after plasmapheresis, approximately 64.6% of circulating Basiliximab was removed. Plasmapheresis removes substantial amounts of Basiliximab. Therefore, supplemental Basiliximab should be given after plasmapheresis to maintain the desired duration of IL-2R saturation.

(PDF same-day service: $19.90)

Accession: 047230853

PMID: 11136200

DOI: 10.1016/s0272-6386(01)90008-3

Related references

Sequential blood level monitoring of basiliximab during multisession plasmapheresis in a kidney transplant recipient. Transplantation Proceedings 37(2): 875-878, 2005

Removal of anti acetylcholine receptor antibody by plasma exchange double filtration plasmapheresis and immunoadsorbent plasmapheresis. Oda, T (Ed ) Isao (International Society For Artificial Organs) Press Publication, No 312 Therapeutic Plasmapheresis; Seventh Symposium, Tokyo, Japan, June 5-6, 1987 Xii+515p Isao Press: Cleveland, Ohio, Usa Illus Paper 305-307, 1988

Selectivity of ldl removal by double filtration and dextran sulfate cellulose column plasmapheresis and combination treatment by plasmapheresis and drugs for familial hypercholesterolemia. Oda, Thiokawa And N. Inoue. Isao (international Society For Artificial Organs) Press Publication, No. 311. Proceedings Of The First International Congress Of The World Apheresis Association: Therapeutic Plasmapheresis (vi); Tokyo, Japan, May . Xvi 810p. Isao Press: Cleveland, Ohio, Usa. Illus. Paper. 584-589, 1987

Comparison of selectivity of ldl removal by double filtration and dextran sulfate cellulose column plasmapheresis and changes of subfractionated plasma lipoproteins after plasmapheresis in heterozygous familial hypercholesterolemia. Metabolism Clinical & Experimental 36(5): 419-425, 1987

Combined use of rituximab and plasmapheresis pre-transplant increases post-transplant infections in renal transplant recipients with basiliximab induction therapy. Transplant Infectious Disease 15(6): 559-568, 2014

Tacrolimus-Basiliximab versus Cyclosporine-Basiliximab in renal transplantation "de novo": acute rejection and complications. Transplantation Proceedings 35(5): 1694-1696, 2003

Removal of immunosuppressive factors in serum of cancer patient by double filtration plasmapheresis simultaneous use of double filtration plasmapheresis and adsorbent. Artificial Organs 9(3): 311, 1985

Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 78(10): 1488-1495, 2004

Vancomycin removal by plasmapheresis. Annals of PharmacoTherapy 30(9): 1038-1038, 1996

Removal of 10-hydroxycarbazepine by plasmapheresis. Therapeutic Drug Monitoring 23(4): 374-379, 2001